Q1 Earnings Forecast for XOMA Issued By Leerink Partnrs

XOMA Co. (NASDAQ:XOMA) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of XOMA in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger forecasts that the biotechnology company will earn ($0.31) per share for the quarter. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.00 EPS and FY2029 earnings at $8.86 EPS.

XOMA has been the topic of several other reports. StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th. HC Wainwright reaffirmed a “buy” rating and issued a $104.00 target price on shares of XOMA in a research report on Wednesday.

XOMA Stock Up 0.0 %

XOMA stock opened at $20.90 on Wednesday. XOMA has a fifty-two week low of $19.92 and a fifty-two week high of $35.00. The company has a market capitalization of $246.26 million, a price-to-earnings ratio of -6.01 and a beta of 1.00. The business’s 50 day moving average price is $24.55 and its two-hundred day moving average price is $27.24. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.75 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its stake in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the last quarter. New York State Common Retirement Fund increased its holdings in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after buying an additional 800 shares in the last quarter. Wells Fargo & Company MN raised its position in XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,183 shares during the last quarter. Bank of America Corp DE lifted its stake in XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,009 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of XOMA during the 4th quarter valued at about $206,000. Institutional investors own 95.92% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.20% of the stock is currently owned by company insiders.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.